LTS Lohmann, a pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (TTS), Oral Thin Films (OTF) and Micro Array Patches (MAP), has acquired the Sorrel wearable injection device business headquartered in Netanya, Israel, a part of the Eitan Medical Ltd.

In a statement, LTS Lohmann said that the acquisition is a crucial step in the company’s strategy to broaden its portfolio of drug delivery platforms. Sorrel’s large volume wearable injector technologies will enable LTS to go beyond its current passive technology offerings. It opens new opportunities for LTS to support pharma partners in the field of large molecules and biologics.

Bas van Buijtenen, CEO of LTS, said: “The acquisition of the Sorrel platform catapults LTS into the world of drug delivery for large molecules, and fulfils our mission to bring empowering solutions to patients that rely on cumbersome and expensive therapies requiring in-clinic administration or multiple injections. Sorrel’s solutions set a new standard for performance, quality, reliability, and patient convenience in wearable injection devices. The Sorrel platform is now ready for commercial launch and will accelerate its scale-up within LTS, benefiting from LTS’s global reach and reputation. We are excited to welcome Dr. Andrei Yosef and his talented team to our organization.”

Andrei Yosef, general manager of Sorrel said: “The acquisition by LTS will accelerate the growth of Sorrel and will benefit our multiple pharma partners. Sorrel’s platform commercial launch is planned for this year together with additional clinical trials with our pharma partners. LTS with its reputation, strong leadership, scale, and combination product capabilities will expedite our growth. Sorrel’s patient-centric on-body drug delivery platform is improving patient comfort and adherence with a reliable easy to use drug delivery device for self-administration at home.”